ABVX

About Abivax SA American Depositary Shares (ABVX) Stock

Abivax SA American Depositary Shares (ABVX) closed the 2026-09-18 session at $105.04, down 1.82% versus the previous close (-1.95). The stock opened at $107.00 and traded between $103.89 and $107.19 during that session. Session trading volume was 876K shares. The volume-weighted average price (VWAP) is $104.95.

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Abivax SA American Depositary Shares has a market capitalization of $9.17 billion. ABVX is listed on the XNAS exchange. The company employs approximately 69 people. The recorded listing date is 2023-10-20.

On this page you can find market ABVX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors.